Population-Level Effectiveness of an Inactivated Whole-Virion COVID-19 Vaccine: A Test Negative Case-Control Study in the Dominican Republic.
Eddy Pérez-ThenMarija MiricHan-Zhu QianYing Qing ChenYixin WangVirginia VallejoWanda QuezadaMelissa FlaquerJuan OlivoJean CastilloNatalia GarcíaKatherine CalderónScarlet CuetoBienvenido VerasMiguel RussoIndira JiménezSorileydi GuzmánLuz GarabitoEvelyn CuetoFátima ColomboDominga TaverasDania TorresJeannette BaezJose YunenEllen KoenigEladio PérezOscar LópezFior Estephanie Severino MedinaXuanyi WangYiming ShaoSten H Vermundnull nullPublished in: Open forum infectious diseases (2023)
Given the ancestral and delta viral variants circulating during this study period, our results suggest that the inactivated COVID-19 vaccine offered moderate protection against symptomatic SARS-CoV-2 infections and high protection against COVID-19-related hospitalizations and assisted ventilation. This is reassuring given that, as of August 2022, an estimated 2.6 billion inactivated CoronaVac vaccine doses had been administered worldwide. This vaccine will become a basis for developing multivalent vaccine against the currently circulating omicron variant.